Prostate Cancer Clinical Trials
The Louis Warschaw Prostate Cancer Center offers standard treatments, as well as new prostate cancer drugs that are being tested for their effectiveness. Depending on your diagnosis, your doctor may recommend that you enroll in a prostate cancer clinical trial. Clinical trials test new drugs, new combinations of drugs or new anticancer treatment strategies.
If you are interested in participating in a prostate cancer clinical trial, a Prostate Cancer Center research specialist will provide you with a written explanation of the proposed research treatment program, including risks and benefits. Your doctor or nurse will answer questions you may have and will ask you to sign a consent form that includes useful information on the specific form of cancer and the research treatment.
Research treatments offered by the Louis Warschaw Prostate Cancer Center are reviewed at a number of levels nationally and/or locally to ensure both the protection of patients' rights and the scientific merit of the research. The Louis Warschaw Prostate Cancer Center will not enroll you in a prostate cancer research treatment without your understanding, agreement, and consent. You may withdraw at any time from a research treatment. This will not affect the quality of care you will receive at the Louis Warschaw Prosate Cancer Center.
Click on the links below for information on contact, objective (study aims and relevance to patient care and scientific understanding), patient eligibility (required conditions for acceptance), schema (study procedures) and potential risks.
For additional information about our clinical trials, please feel free to contact us.| Louis Warschaw Prostate Cancer Center |
| Phone: (310) 423-7600 |
| Send Us a Message |
You will need Adobe® Reader® to view and print these documents from your desktop. If you do not have this software, you can download it FREE from Adobe's website.
Hormone-Sensitive Prostate Cancer
Hormone-Refractory Prostate Cancer
A Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Asymptomatic Patients with Metastatic Androgen Independent Prostate Cancer
Cooperative Group Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 6443
A Phase II Study of the Efficacy and Safety of AP23573 in Patients with Taxane-Resistant Androgen-Independent Prostate Cancer
Industry Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 6712
A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men with Hormone Refractory Prostate Cancer
Cooperative Group Trial
Principal Investigator
David Agus, MD
IRB No. 7847
A Phase II Evaluation of EMD121974 (NSC, Cilengitide) in Patients with Non-Metastatic Androgen Independent Prostate Cancer
Cooperative Group Trial
Principal Investigator
David Agus, MD
IRB No. 7895
A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study of CP-751,871 in Combination with Docetaxel/Prednisone in Chemotherapy-naïve (Arm A) and Docetaxel/Prednisone Refractory (Arm B) Patients with Hormone Insensitive Prostate Cancer
Industry Trial
Principal Investigator
David Agus, MD
IRB No. 8924
A Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer
Industry Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 10667
Phase Ib/II Evaluation of RAD001 with docetaxel and bevacizumab in Patients with Metastatic Androgen Independent Prostate Cancer
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 10405
A Phase 2 Trial of TPI 287 in Patients with Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment with One Prior Taxane Regimen
Industry Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 11669
A Phase I/II, Open-Label, Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of TAK-700 in Advanced Prostate Cancer
Industry Trial
Principal Investigator
David Agus, MD
IRB No. 14175
A Phase II Study of Ixabepilone Prior to Surgery for High-Risk Localized Prostate Cancer
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 13963
A Phase I Dose Escalation Study of BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Industry Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 15143
Other
Prostate Patient Profiles Project (P4)
Institutional Trial
Principal Investigator
David Agus, MD
IRB No. 3979
Prostate Outcomes Project (POP). A Decision Outcomes Study of Patients with Newly Diagnosed Prostate Cancer and Treatment
Institutional Trial
Principal Investigator
David Agus, MD
IRB No. 3840
Urine Markers to Determine Status in Prostate Cancer Patients Treated with Local Radiation
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 11986
A Pilot Study Utilizing Molecular Profiling of Patient's Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Investigator Initiated Trial
Principal Investigator
David Agus, MD
IRB No. 11306
Characterization of Circulating Tumor Cells of Metastatic Prostate Cancer Patients Using Gene Markers
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 11799
Characterization of Circulation Tumor Cells in Prostate Cancer Patients Prior to Surgery
Investigator Initiated Trial
Principal Investigator
Mitchell Gross, MD, PhD
IRB No. 16210
